They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

"Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so," ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

‘They hate it’: House Minority Whip describes Americans' rejection of Trump's tax bill Widow of officer who died by suicide ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.